XELIRI

XELIRI is a chemotherapy regimen used in the treatment of various types of cancer, particularly colorectal cancer. The regimen combines two chemotherapeutic agents: capecitabine (Xeloda) and irinotecan (Camptosar). This combination is designed to enhance the effectiveness of cancer treatment by utilizing the synergistic effects of both drugs.

Components of XELIRI

• Capecitabine: An oral prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body. It interferes with the synthesis of DNA and RNA by inhibiting the enzyme thymidylate synthase, which is essential for DNA replication.
• Irinotecan: A topoisomerase inhibitor that prevents DNA from unwinding, which is necessary for replication and transcription. It is administered intravenously and is converted in the body to its active form, SN-38.

Mechanism of Action

The combination of capecitabine and irinotecan works by targeting different pathways involved in cancer cell proliferation. Capecitabine, once converted to 5-FU, disrupts DNA synthesis, while irinotecan inhibits the enzyme topoisomerase I, leading to DNA damage and cell death. This dual mechanism increases the likelihood of killing cancer cells and reducing tumor size.

Indications

XELIRI is primarily indicated for the treatment of metastatic colorectal cancer, but it may also be used in other types of cancer as determined by a healthcare provider. It is often considered when patients are not suitable candidates for other chemotherapy regimens or when other treatments have failed.

Administration and Dosage

The administration of XELIRI involves a specific schedule and dosage, which is determined by the oncologist based on the patient's overall health, type of cancer, and response to treatment. Capecitabine is typically taken orally, while irinotecan is given as an intravenous infusion.

Side Effects

Common side effects of XELIRI include:

• Nausea
• Vomiting
• Diarrhea
• Fatigue
• Neutropenia
• Alopecia

Patients undergoing XELIRI treatment are closely monitored for these side effects, and supportive care measures are provided to manage them.

Related Pages

• Colorectal cancer
• Chemotherapy
• Capecitabine
• Irinotecan
• 5-fluorouracil
• Topoisomerase inhibitor

See Also

• FOLFIRI
• FOLFOX
• XELOX